Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage.

Tin Tin Htar M, Sings HL, Syrochkina M, Taysi B, Hilton B, Schmitt HJ, Gessner BD, Jodar L.

Expert Rev Vaccines. 2019 Oct 7. doi: 10.1080/14760584.2019.1675521. [Epub ahead of print]

PMID:
31587592
2.

Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.

McLaughlin JM, Jiang Q, Gessner BD, Swerdlow DL, Sings HL, Isturiz RE, Jodar L.

Vaccine. 2019 Oct 8;37(43):6310-6316. doi: 10.1016/j.vaccine.2019.08.059. Epub 2019 Sep 12. Review.

3.

Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines.

Gessner BD, Sings HL, Jodar L.

Lancet Infect Dis. 2019 Jul;19(7):692-693. doi: 10.1016/S1473-3099(19)30270-1. No abstract available.

PMID:
31250816
4.

A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.

Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.

Vaccine. 2019 Jul 9;37(30):4147-4154. doi: 10.1016/j.vaccine.2019.05.065. Epub 2019 May 31.

5.

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium.

Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA.

Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1. Epub 2018 Nov 20. No abstract available.

6.

Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada".

Wilson MR, Wasserman M, Jadavji T, Postma M, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh R.

Infect Dis Ther. 2018 Dec;7(4):539-543. doi: 10.1007/s40121-018-0221-2. Epub 2018 Nov 8. No abstract available.

7.

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.

Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L.

Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920.

8.

Response to Mungall et al. letter to the editor on Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Gessner B, Jodar L.

Expert Rev Vaccines. 2018 Aug;17(8):669-671. doi: 10.1080/14760584.2018.1506207. Epub 2018 Aug 2. No abstract available.

PMID:
30071169
9.

A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.

Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Neuzil KM, O'Brien KL, Wunderink RG, Grobbee DE, Bonten MJM, Jodar L.

Vaccine. 2019 Sep 10;37(38):5777-5787. doi: 10.1016/j.vaccine.2018.05.097. Epub 2018 May 31.

10.

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.

McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, Ramirez JA, Jodar L.

Clin Infect Dis. 2018 Oct 30;67(10):1498-1506. doi: 10.1093/cid/ciy312.

11.

Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine.

Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R.

Expert Rev Vaccines. 2018 Jan;17(1):71-78. doi: 10.1080/14760584.2018.1409116. Epub 2017 Nov 29. Review.

PMID:
29164952
12.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

13.

Streptococcus pneumoniae serotype 19A: worldwide epidemiology.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L.

Expert Rev Vaccines. 2017 Oct;16(10):1007-1027. doi: 10.1080/14760584.2017.1362339. Epub 2017 Aug 28. Review.

PMID:
28783380
14.

Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.

Sings HL.

Vaccine. 2017 Sep 25;35(40):5406-5417. doi: 10.1016/j.vaccine.2017.05.075. Epub 2017 Jun 9.

PMID:
28602602
15.
16.

Pneumococcal conjugate vaccine use in adults.

Isturiz RE, Schmoele-Thoma B, Scott DA, Jodar L, Webber C, Sings HL, Paradiso P.

Expert Rev Vaccines. 2016;15(3):279-93. doi: 10.1586/14760584.2016.1132171. Epub 2015 Dec 29. Review.

PMID:
26651847
17.

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ.

Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Review.

PMID:
26107345
18.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

19.

Long-term study of a quadrivalent human papillomavirus vaccine.

Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A.

Pediatrics. 2014 Sep;134(3):e657-65. doi: 10.1542/peds.2013-4144. Epub 2014 Aug 18.

PMID:
25136050
20.

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.

Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9.

PMID:
24118703
21.

Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.

Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EI.

J Adolesc Health. 2013 Mar;52(3):322-9. doi: 10.1016/j.jadohealth.2012.07.003. Epub 2012 Aug 15.

PMID:
23299013
22.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators.

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11.

PMID:
23081753
23.

Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease.

Ruiz ÁM, Ruiz JE, Gavilanes AV, Eriksson T, Lehtinen M, Pérez G, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group.

J Infect Dis. 2012 Dec 15;206(12):1887-96. doi: 10.1093/infdis/jis612. Epub 2012 Oct 12.

PMID:
23066159
24.

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):81-87.e4; quiz e5. doi: 10.1016/j.cgh.2012.10.006. Epub 2012 Oct 10.

PMID:
23064222
25.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-618.e5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
26.

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group.

BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401.

27.

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females.

Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ.

Vaccine. 2012 Jun 13;30(28):4284-91. doi: 10.1016/j.vaccine.2012.02.079. Epub 2012 Mar 18.

PMID:
22433961
28.

The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.

Haupt RM, Sings HL.

J Adolesc Health. 2011 Nov;49(5):467-75. doi: 10.1016/j.jadohealth.2011.07.003. Epub 2011 Sep 9.

PMID:
22018560
29.

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.

Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators.

Int J Cancer. 2011 Dec 1;129(11):2632-42. doi: 10.1002/ijc.25940. Epub 2011 Apr 13.

30.

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group.

Sex Transm Infect. 2011 Aug;87(5):372-6. doi: 10.1136/sti.2010.044354. Epub 2011 Apr 6.

31.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

32.

Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.

Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group.

Int J Cancer. 2011 Mar 15;128(6):1344-53. doi: 10.1002/ijc.25723. Epub 2011 Jan 12.

33.

The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.

Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM; FUTURE I, II and III Investigators.

Int J Cancer. 2011 Mar 15;128(6):1354-62. doi: 10.1002/ijc.25470.

34.

Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel.

Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, Sings HL, Haupt RM, Garner EI; Protocol 025 Investigators.

Pediatrics. 2010 Jun;125(6):1142-51. doi: 10.1542/peds.2009-2336. Epub 2010 May 3.

PMID:
20439595
35.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
36.

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.

Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS.

Pediatr Infect Dis J. 2010 Feb;29(2):95-101. doi: 10.1097/INF.0b013e3181b77906.

PMID:
19952863
37.

Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.

Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EI; Quadrivalent Human Papillomavirus Vaccine Phase III Investigators.

Obstet Gynecol. 2009 Dec;114(6):1179-88. doi: 10.1097/AOG.0b013e3181c2ca21.

PMID:
19935017
38.

Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV.

Mast TC, Zhu X, Demuro-Mercon C, Cummings HW, Sings HL, Ferris DG.

Curr Med Res Opin. 2009 Nov;25(11):2609-19. doi: 10.1185/03007990903238786.

PMID:
19739938
39.

Human papillomavirus infections and vulvar disease development.

Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84. doi: 10.1158/1055-9965.EPI-09-0067.

40.

Incidence and risk factors for genital Chlamydia trachomatis infection: a 4-year prospective cohort study.

Skjeldestad FE, Marsico MA, Sings HL, Nordbø SA, Størvold G.

Sex Transm Dis. 2009 May;36(5):273-9. doi: 10.1097/OLQ.0b013e3181924386.

PMID:
19265733
41.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

PMID:
19236279
42.

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA.

J Infect Dis. 2009 Mar 15;199(6):805-14. doi: 10.1086/597071.

PMID:
19199546
43.

Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA.

Wien Klin Wochenschr. 2008;120(21-22):666-71. doi: 10.1007/s00508-008-1093-3.

PMID:
19116707
44.

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E.

Arch Gynecol Obstet. 2009 Jun;279(6):803-7. doi: 10.1007/s00404-008-0806-1. Epub 2008 Oct 21.

PMID:
18936950
45.

Prophylactic HPV vaccines: new interventions for cancer control.

Barr E, Sings HL.

Vaccine. 2008 Nov 18;26(49):6244-57. doi: 10.1016/j.vaccine.2008.07.056. Epub 2008 Aug 9. Review.

PMID:
18694795
46.

Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators.

Guo L, Ye Z, Ujjainwalla F, Sings HL, Sebhat IK, Huber J, Weinberg DH, Tang R, MacNeil T, Tamvakopoulos C, Peng Q, MacIntyre E, van der Ploeg LH, Goulet MT, Wyvratt MJ, Nargund RP.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3242-7. doi: 10.1016/j.bmcl.2008.04.049. Epub 2008 Apr 25.

PMID:
18479920
47.

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.

Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM.

Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.

PMID:
18313445
48.

Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists.

Cai B, Ronnett BM, Stoler M, Ferenczy A, Kurman RJ, Sadow D, Alvarez F, Pearson J, Sings HL, Barr E, Liaw KL.

Am J Surg Pathol. 2007 Dec;31(12):1854-60.

PMID:
18043039
49.

Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.

Skjeldestad FE, Mehta V, Sings HL, Øvreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, Esser MT, Liaw KL.

Acta Obstet Gynecol Scand. 2008;87(1):81-8.

PMID:
17943470
50.

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J.

Lancet. 2007 May 19;369(9574):1693-702.

PMID:
17512854

Supplemental Content

Loading ...
Support Center